Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Onconova Therapeutics stock (ONTX)

Buy Onconova Therapeutics stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Our top picks for where to buy Onconova Therapeutics stock

Best for beginners

Go to site
Get up to $1,000 in stock
  • No-cost financial planning and automated investing
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options, with no options contract fees

Top pick for advanced traders

Go to site
Get up to $5,000 cash
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Our pick for cash sweep

Go to site
Advanced charts and trading tools
  • Trade stocks, ETFs and equity options without commission and $0 option contract fees
  • Earn up to 8.1% APY on your uninvested cash
  • Get a 1.5% match in cash on transferred assets up to $300 or up to 15 free fractional shares worth between $2 and $2,000

How to buy Onconova Therapeutics stock

  1. Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – ONTX. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Onconova Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 5 of 5
Name Product Ratings Available asset types Minimum deposit Advisory fee Cash sweep APY Signup bonus
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
★★★★★
Stocks, Mutual funds, ETFs, Alternatives
$0
$0
0.02%
Get up to $1,000 in stock
Commission-free stocks, ETFs and options, with no options per-contract fees. Plus, a no-cost robo-advisor and complimentary access to certified financial planners (CFPs).
Tastytrade
Finder Score: 4.4 / 5: ★★★★★
Tastytrade
★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
$0
$0
N/A
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
Moomoo
Finder Score: 4.7 / 5: ★★★★★
Exclusive
Moomoo
★★★★★
Stocks, Options, ETFs
$0
$0
Up to 8.10%
Choose a 1.5% match or up to 15 free fractional shares
No commission stock, ETF and options trades, with $0 equity options contract fees, low margin rates and advanced trading tools.
Public.com
Finder Score: 4.2 / 5: ★★★★★
Public.com
★★★★★
Stocks, Bonds, Options, ETFs, Cryptocurrency, Alternatives, Treasury Bills, High-yield cash account
$0
$0
5.1%
Get up to $10,000 and transfer fees covered
Build a diversified portfolio of stocks, bonds, options, ETFs, crypto and alternative assets, with a high-yield cash account and options contract rebates.
Interactive Brokers
Finder Score: 4.3 / 5: ★★★★★
Interactive Brokers
★★★★★
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex, Treasury Bills
$0
$0
3.83% Lite
4.83% Pro
N/A
Zero commission stock and ETF trades, with global market access and pro-grade trading tools.
loading

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

AS SEEN ON:

Onconova Therapeutics is a biotechnology business based in the US. Onconova Therapeutics shares (ONTX) are listed on the NASDAQ and all prices are listed in US Dollars. Onconova Therapeutics employs 16 staff and has a trailing 12-month revenue of around $226,000.

Onconova Therapeutics stock price (NASDAQ: ONTX)

Use our graph to track the performance of ONTX stocks over time.

Onconova Therapeutics shares at a glance

Information last updated 2024-06-02.
Latest market close$7.93
52-week range$0.55 - $7.97
50-day moving average $0.82
200-day moving average $0.78
Wall St. target price$8.33
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.96

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Is it a good time to buy Onconova Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Onconova Therapeutics price performance over time

Historical closes compared with the close of $7.93 from 2024-04-03

1 week (2024-06-10) N/A
1 month (2024-05-17) N/A
3 months (2024-03-21) 844.05%
6 months (2023-12-21) 1,032.86%
1 year (2023-06-21) 608.04%
2 years (2022-06-21) 544.72%
3 years (2021-06-21) 16.11%
5 years (2019-06-21) 56.25

Onconova Therapeutics financials

Revenue TTM $226,000
Gross profit TTM $226,000
Return on assets TTM -38.07%
Return on equity TTM -84.3%
Profit margin 0%
Book value $0.69
Market Capitalization $20.9 million

TTM: trailing 12 months

Onconova Therapeutics share dividends

We're not expecting Onconova Therapeutics to pay a dividend over the next 12 months.

Have Onconova Therapeutics's shares ever split?

Onconova Therapeutics's shares were split on a 1:15 basis on 20 May 2021. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Onconova Therapeutics shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Onconova Therapeutics shares which in turn could have impacted Onconova Therapeutics's share price.

Onconova Therapeutics share price volatility

Over the last 12 months, Onconova Therapeutics's shares have ranged in value from as little as $0.5509 up to $7.97. A popular way to gauge a stock's volatility is its "beta".

ONTX.US volatility(beta: 1.35)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Onconova Therapeutics's is 1.349. This would suggest that Onconova Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Onconova Therapeutics overview

Onconova Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc.

Frequently asked questions

What percentage of Onconova Therapeutics is owned by insiders or institutions?
Currently 0.779% of Onconova Therapeutics shares are held by insiders and 7.949% by institutions.
How many people work for Onconova Therapeutics?
Latest data suggests 16 work at Onconova Therapeutics.
When does the fiscal year end for Onconova Therapeutics?
Onconova Therapeutics's fiscal year ends in December.
Where is Onconova Therapeutics based?
Onconova Therapeutics's address is: 12 Penns Trail, Newtown, PA, United States, 18940
What is Onconova Therapeutics's ISIN number?
Onconova Therapeutics's international securities identification number is: US68232V8019
What is Onconova Therapeutics's CUSIP number?
Onconova Therapeutics's Committee on Uniform Securities Identification Procedures number is: 68232V405

More guides on Finder

Ask a Question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site